High SLC20A1 Expression Is Associated With Poor Prognoses in Claudin-low and Basal-like Breast Cancers
High SLC20A1 Expression Is Associated With Poor Prognoses in Claudin-low and Basal-like Breast Cancers
复制标题
DOI：
10.21873/anticanres.14750
复制
发表时间：
2021-01-01
影响因子：
2
通讯作者：
Akimoto, Kazunori
中科院分区：
文献类型：
--
作者：
Onaga, Chotaro;Tamori, Shoma;Akimoto, Kazunori
背景/目的：SLC 20 A1已被确定为ER+乳腺癌的预后标志物。然而，SLC 20 A1表达在ER+型以外的乳腺癌亚型中的作用仍不清楚。材料与方法：下载并分析基因组学数据集，并评估使用靶向siRNA敲低SLC 20 A1对细胞活力和肿瘤球形成的影响。结果：ER+、claudin-低或基底细胞样乳腺癌的SLC 20 A1（高）患者表现出较差的预后。接受放疗的SLC 20 A1（高）患者的临床结局较差。SLC 20 A1敲低抑制MDA-MB 231（封闭蛋白-低）、MDA-MB 468（基底样）和MCF-7（ER+）细胞的活力，以及ALDH 1（高）细胞的肿瘤球形成。这些结果表明，SLC 20 A1参与癌症进展，并有助于ER+，claudin低和基底样乳腺癌患者的临床结果。结论：SLC 20 A1是ER+、claudin-低和基底细胞样乳腺癌的潜在预后标志物和治疗靶点。
Background/Aim: SLC20A1 has been identified as a prognostic marker in ER+ breast cancer. However, the role of SLC20A1 expression in breast cancer subtypes other than the ER+ types remains unclear. Materials and Methods: Genomics datasets were downloaded and analyzed, and the effect of SLC20A1 knockdown using targeted siRNA on cell viability and tumor-sphere formation was assessed. Results: SLC20A1(high) patients with ER+, claudin-low or basal-like breast cancers showed poor prognoses. SLC20A1(high) patients treated with radiotherapy had poor clinical outcomes. SLC20A1 knockdown suppressed the viability of MDA-MB 231 (claudin-low), MDA-MB 468 (basal-like) and MCF-7 (ER+) cells, and tumor-sphere formation by ALDH1(high) cells. These results suggest that SLC20A1 is involved in cancer progression and contributes to clinical outcomes in patients with ER+, claudin-low and basal-like breast cancers. Conclusion: SLC20A1 is a potential prognostic marker and therapeutic target in ER+, claudin-low and basal-like breast cancers.